journal
https://read.qxmd.com/read/36928055/description-of-supportive-care-and-feasibility-of-physical-exercise-program-to-improve-quality-of-life-in-advanced-melanoma-patients
#1
JOURNAL ARTICLE
Marie Boileau, Carole Templier, Edouard Massip, Clémentine Dehoux, Véronique Dziwniel, Claudine Fabre, André Thevenon, Laurent Mortier
Physical activity is the first-line treatment of cancer-related fatigue. It has shown benefits on patient's quality of life (QoL) when practiced during and after treatment. New treatments have drastically changed the prognosis of melanoma. Still, few data are available about research program of supportive care in advanced melanoma. The primary outcome was to assess the feasibility of setting up a prospective study evaluating the benefits of Adapted Physical Activity (APA) on the QoL of patients with advanced melanoma...
March 17, 2023: Melanoma Research
https://read.qxmd.com/read/36919691/real-life-use-of-trametinib-after-immunotherapy-failure-in-braf-wild-type-advanced-melanoma
#2
JOURNAL ARTICLE
Tristan Pigné, Marie Lévy, Océane Ducharme, Caroline Dutriaux, Emilie Gerard, Anne Pham-Ledard, Marie Beylot-Barry, Sorilla Prey
BRAFV600 wild-type advanced melanomas quickly reach a therapeutic dead-end, after immunotherapy failure. Even if preclinical studies have suggested sensitivity to MEK inhibitors such as trametinib in NRAS, NF1 or GNA mutated melanoma, therapeutic options are limited for these patients. We present a retrospective monocentric study of 22 patients with advanced melanoma treated by trametinib after immunotherapy resistance. Melanomas harboured NRAS (20), NF1 (1) or GNA11 (1) mutations. For most of them (18), anti-PD1 was associated with trametinib...
March 15, 2023: Melanoma Research
https://read.qxmd.com/read/36866640/clinical-response-under-mek-inhibitor-alone-in-metastatic-melanoma-with-a-novel-fusion-involving-the-raf1-gene
#3
JOURNAL ARTICLE
Marie Boileau, Clotilde Descarpentries, Guillaume Delzenne, Victorine Trentesaux, Anna Greliak, Philippe Jamme, Philippe Marchetti, Laurent Mortier
Currently, in the absence of BRAFV600 mutation, the management of advanced melanomas is based on immunotherapies, but only half of the patients are responders. RAF1 (also named CRAF) fusions occur in 1-2.1% of wild-type melanomas. Preclinical data suggest that the presence of RAF fusion may be sensitive to MEK inhibitors. We report the case of a patient with an advanced melanoma harboring an EFCC1-RAF1 fusion who showed a clinical benefit from and a partial response to a MEK inhibitor.
March 3, 2023: Melanoma Research
https://read.qxmd.com/read/36866632/prognosis-of-polypoid-melanoma-a-comparative-study-with-non-polypoid-melanomas
#4
JOURNAL ARTICLE
Velma Y Jasso-Sosa, Leonardo S Lino-Silva, Marín G Escobar-Jiménez, Joab R Galván-Bustillos, Dorian Y García-Ortega, Rosa A Salcedo-Hernández, César Zepeda-Najar, Pedro Frías-Fernández
Polypoid melanoma is considered an exophytic and frequently non-pigmented variant of nodular melanoma with an adverse prognosis; however, very few studies have been published about it with contradictory results. Therefore, our objective was to determine the prognostic value of this configuration in melanomas. A transversal retrospective study of 724 cases was analyzed according to the main configuration (polypoid vs. non-polypoid) regarding their clinicopathologic characteristics and survival analysis. Of the 724 cases, 35 (4...
March 3, 2023: Melanoma Research
https://read.qxmd.com/read/36866631/the-influence-of-metastatic-patterns-and-tumor-load-on-therapeutic-efficacy-of-immunotherapy-in-patients-with-metastatic-melanoma-as-determined-by-quantitative-pet-parameters-using-18f-fluorodeoxyglucose-pet-computed-tomography
#5
JOURNAL ARTICLE
Cornelius Berberich, Mona Mustafa, Yize Zhuwu, Jochen Gaa, Angela Krackhardt, Stephan G Nekolla
The introduction of immunotherapy was a revolution in the treatment of metastatic melanoma. Nevertheless, there are only few clinical parameters to predict response to immunotherapy. The purpose of this study was to identify metastatic patterns that can predict response by using noninvasive 18F-FDG PET/CT imaging. In 93 immunotherapy-treated patients, total metabolic tumor volume (MTV) was measured before and after treatment. The differences were compared to quantify therapy response. Patients were divided into seven subgroups regarding the affected organ systems...
March 3, 2023: Melanoma Research
https://read.qxmd.com/read/36847301/patients-with-a-history-of-atopy-have-fewer-cutaneous-melanomas-than-those-without-atopy-a-cross-sectional-study-in-496-patients-at-risk-of-skin-cancers
#6
JOURNAL ARTICLE
Jenni Komulainen, Hanna Siiskonen, Salla Haimakainen, Emilia Kanasuo, Rauno J Harvima, Ilkka T Harvima
The connection between atopy and skin cancers may be related to the stimulation of protective immune response, for example, through autoreactive immunoglobulin-E (IgE), or to the predisposition to carcinogenesis through chronic inflammation. The aim of this study was to investigate whether a past or present atopic disorder is associated with cutaneous photodamage, pigment cell nevi and skin cancers. For this, adult subjects at risk of any type of skin cancer (aged 21-79 years, 250 males, 246 females, 94 with immunosuppression) were examined for past or present malignancies in skin and extracutaneous site (ECS), photodamage, nevi, past or present atopic disorder in skin or mucus membranes, and possible other cancer-related factors...
February 28, 2023: Melanoma Research
https://read.qxmd.com/read/36805567/methylation-of-nonessential-genes-in-cutaneous-melanoma-rule-out-hypothesis
#7
JOURNAL ARTICLE
Ivan P Gorlov, Kathleen Conway, Sharon N Edmiston, Eloise A Parrish, Honglin Hao, Christopher I Amos, Spiridon Tsavachidis, Olga Y Gorlova, Colin Begg, Eva Hernando, Chao Cheng, Ronglai Shen, Irene Orlow, Li Luo, Marc S Ernstoff, Pei Fen Kuan, David W Ollila, Yihsuan S Tsai, Marianne Berwick, Nancy E Thomas
Differential methylation plays an important role in melanoma development and is associated with survival, progression and response to treatment. However, the mechanisms by which methylation promotes melanoma development are poorly understood. The traditional explanation of selective advantage provided by differential methylation postulates that hypermethylation of regulatory 5'-cytosine-phosphate-guanine-3' dinucleotides (CpGs) downregulates the expression of tumor suppressor genes and therefore promotes tumorigenesis...
February 20, 2023: Melanoma Research
https://read.qxmd.com/read/36735464/dna-methylation-of-gitr-ox40-4-1bb-cd27-and-cd40-correlates-with-bap1-aberrancy-and-prognosis-in-uveal-melanoma
#8
JOURNAL ARTICLE
Friederike Hoffmann, Anne Fröhlich, Judith Sirokay, Luka de Vos, Romina Zarbl, Jörn Dietrich, Sebastian Strieth, Jennifer Landsberg, Dimo Dietrich
Uveal melanoma represents an aggressive tumor that responds mostly poorly to established melanoma treatments. Comprehensive methylation profiling of the next-generation immunotherapeutic target genes, for example, members of the tumor necrosis factor receptor superfamily, might allow for the development of companion predictive biomarkers. We have analyzed CpG sites within the immune checkpoint genes GITR, OX40, 4-1BB, CD27, and CD40 probed by the Illumina Infinium HumanMethylation450 BeadChip in N = 80 uveal melanomas included in The Cancer Genome Atlas with regard to BAP1 aberrancy, mRNA expression, and overall survival...
February 1, 2023: Melanoma Research
https://read.qxmd.com/read/36719926/molecular-profiling-of-primary-uveal-melanoma-results-of-a-polish-cohort
#9
JOURNAL ARTICLE
Artur Kowalik, Pawel Karpinski, Anna Markiewicz, Jolanta Orlowska-Heitzman, Bozena Romanowska-Dixon, Piotr Donizy, Mai P Hoang
There is no published data regarding the molecular alterations of Polish patients with primary uveal melanoma. We performed whole exome sequencing of 20 primary uveal melanomas (UMs), 10 metastasizing and 10 non-metastasizing cases to identify significant molecular alterations. We detected mutations and copy number variants in the BAP1 gene in 50% (10 cases) of the cases. GNA11 mutations were detected in 50% (10 cases) including nine p.Q209L and one p.R183C. GNAQ mutations gene were detected in 40% (8 cases) and all were p...
January 30, 2023: Melanoma Research
https://read.qxmd.com/read/36662668/the-human-and-animals-malignant-melanoma-comparative-tumor-models-and-the-role-of-microbiome-in-dogs-and-humans
#10
JOURNAL ARTICLE
Catarina Pinto, Catarina Aluai-Cunha, Andreia Santos
Currently, the most progressively occurring incident cancer is melanoma. The mouse is the most popular model in human melanoma research given its various benefits as a laboratory animal. Nevertheless, unlike humans, mice do not develop melanoma spontaneously, so they need to be genetically manipulated. In opposition, there are several reports of other animals, ranging from wild to domesticated animals, that spontaneously develop melanoma and that have cancer pathways that are similar to those of humans. The influence of the gut microbiome on health and disease is being the aim of many recent studies...
January 20, 2023: Melanoma Research
https://read.qxmd.com/read/36728700/new-technique-for-in-continuity-axillary-and-supraclavicular-lymphadenectomy-for-advanced-metastatic-melanoma-using-intraoperative-image-guidance-a-case-report
#11
JOURNAL ARTICLE
Kantappa Gajanan, Karan Daga, Damian Mullan, Damir Kosutic
Simultaneousinvolvement of the supraclavicular and axillary lymphatic basins is known to occur in metastatic skin cancers. We present the case of a 35-year-old male with metastatic melanoma present in the right neck and axillary lymph nodes. He underwent a combined, in-continuity dissection of both basins using intraoperative ultrasound to ensure full clearance of lymph nodes from the cervicoaxillary canal, which otherwise would have been impossible to achieve without clavicle osteotomy. This allowed us to avoid a division of the clavicle and related morbidity...
December 28, 2022: Melanoma Research
https://read.qxmd.com/read/36580363/regular-use-of-vitamin-d-supplement-is-associated-with-fewer-melanoma-cases-compared-to-non-use-a-cross-sectional-study-in-498-adult-subjects-at-risk-of-skin-cancers
#12
JOURNAL ARTICLE
Emilia Kanasuo, Hanna Siiskonen, Salla Haimakainen, Jenni Komulainen, Ilkka T Harvima
There are conflicting results on the role of vitamin D system in cutaneous carcinogenesis. Therefore, it was investigated whether the use of oral vitamin D supplements associates with photoaging, actinic keratoses, pigment cell nevi, and skin cancers. In this cross-sectional study, 498 adults (aged 21-79 years, 253 males, 245 females, 96 with immunosuppression) subjects at risk of any type of skin cancer were examined, and possible confounding factors were evaluated. The subjects were divided into three groups based on their self-reported use of oral vitamin D supplements: non-use, occasional use, or regular use...
December 28, 2022: Melanoma Research
https://read.qxmd.com/read/36815470/recurrent-hemophagocytic-lymphohistiocytosis-in-advanced-melanoma-treated-with-two-different-braf-mek-inhibitor-regimens
#13
JOURNAL ARTICLE
Jean-Baptiste Le Goubey, Marion Sassier, Ines Nakouri, Michel De Pontville, Laure Césaire, Nicolas Aide, Diane Kottler
No abstract text is available yet for this article.
April 1, 2023: Melanoma Research
https://read.qxmd.com/read/36806616/screening-costs-associated-with-donor-selection-for-fecal-microbiota-transplantation-for-treatment-of-pd-1-refractory-melanoma-patients
#14
JOURNAL ARTICLE
Dylan Fortman, Maria G Pazan Avellan, Drew Hurd, Marc Schwartz, Howard Dubner, Corey Hewitt, Samantha Berton, Scarlett Ernst, Amy Rose, Hong Wangd Hassane Zarour, Diwakar Davar
The gut microbiome acts as a tumor-extrinsic regulator of responses to immune-checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors. Primary resistance to anti-PD-1 ICI can be reversed via responder-derived fecal microbiota transplant (FMT) in patients with refractory melanoma. Efforts to create stool banks for FMT have proved difficult. Therefore, we aimed to establish a novel donor-screening program to generate responder-derived FMT for use in PD-1 refractory melanoma. Candidate PD-1 responder donors and PD-1 refractory recipients were recruited via clinic-based encounters at the University of Pittsburgh Medical Center hospitals...
April 1, 2023: Melanoma Research
https://read.qxmd.com/read/36749114/drug-reactions-with-eosinophilia-and-systemic-symptoms-induced-by-immune-checkpoint-inhibitors-an-international-cohort-of-13-cases
#15
JOURNAL ARTICLE
Saskia Ingen-Housz-Oro, Brigitte Milpied, Benoit Bensaid, Yannick Elshot, Marie Charlotte Brüggen, Michela Starace, Benjamin H Kaffenberger, Cristina Carrera, Anne Pham-Ledard, Azael Freites-Martinez, Paola Sanchez-Pena, Bénédicte Lebrun-Vignes, Lars E French, Vincent Sibaud
Among dermatologic adverse events induced by immune checkpoint inhibitors (ICI), drug reactions with eosinophilia and systemic symptoms (DRESS) have been very rarely reported. The objective of this study is to better define the clinical and histologic features, treatment and prognosis of ICI-related DRESS. This retrospective case series was conducted between 01 January 2015 and 31 December 2021 by the dermatology departments of five international networks involved in drug reactions. Inclusion criteria were age ≥18 years old, DRESS with Regiscar score ≥4 (probable or certain) and ICI as a suspect drug...
April 1, 2023: Melanoma Research
https://read.qxmd.com/read/36545923/preoperative-assessment-of-cutaneous-melanoma-thickness-by-multispectral-dermoscopy
#16
JOURNAL ARTICLE
Laudine Janssen, Sofie Van Kelst, Julie De Smedt, Julie Terrasson, Bart Diricx, Tom Kimpe, Jorien Papeleu, Evelien Verhaeghe, Lieve Brochez, Marjan Garmyn
Preoperative assessment of Breslow thickness by means of sonography and clinical and dermoscopic criteria in white light dermoscopy has been reported, but up until now, the use of multispectral dermoscopy has not been investigated. Aim of this research is to determine whether multispectral dermoscopy and more specifically pigment maps can be used as a predictive marker for Breslow thickness in melanoma. Pigment maps are generated in real time from multispectral dermoscopic images and help to visualize the presence of pigment in a lesion...
February 1, 2023: Melanoma Research
https://read.qxmd.com/read/36545922/immune-related-adverse-events-are-associated-with-therapeutic-efficacy-of-immunotherapy-in-patients-with-melanoma-brain-metastases
#17
JOURNAL ARTICLE
Cecilia W Huo, Indika Gunadasa, Panagiota Gkolia, Mark Shackleton, Martin Hunn
Immunotherapy with T-cell checkpoint inhibitors have changed the treatment landscape for patients with melanoma brain metastases (MBMs), offering increased survival compared with historical outcomes. We sought to identify clinical features associated with intracranial tumour responses or progression-free survival (PFS) in patients with MBMs treated with immunotherapy. Patients with MBMs treated with immunotherapy from August 2013 to March 2020 were identified through local databases. Melanoma disease burdens and immune-related adverse events (irAEs) were assessed retrospectively by review of patient medical records...
February 1, 2023: Melanoma Research
https://read.qxmd.com/read/36545921/real-world-outcomes-of-different-lines-and-sequences-of-treatment-in-braf-positive-advanced-melanoma-patients
#18
JOURNAL ARTICLE
Allison Betof Warner, Ahmad Tarhini, Barinder Kang, Antonio Nakasato, You-Li Ling, Rohan Shah, Jackson Tang, Jeetvan Patel
The objective of this study is to compare efficacy with different treatment sequences and lines of treatment among BRAF V600 mutated (BRAF+) advanced melanoma patients with immunotherapies (IO) and targeted therapies (TT) using real-world data. This was a retrospective cohort study using the Novartis BRAF+ meLanoma patients ObsErvational database, the harmonized customized data from Flatiron and ConcertAI. The study included BRAF+ advanced unresectable melanoma patients treated with first-line (1L) IO or TT between 1 January 2014 and 31 May 2020...
February 1, 2023: Melanoma Research
https://read.qxmd.com/read/36545920/high-expression-of-grb2-associated-binding-protein-3-mrna-predicts-positive-prognosis-in-melanoma
#19
JOURNAL ARTICLE
Chunting Li, Zhenzhen Ye, Yimeng Wang, Guanyu Wang, Qian Zhang, Chunlei Zhang
Malignant melanoma is the most aggressive form of skin cancer, and it is characterized by poor prognosis in patients with metastatic diseases. Accurate prediction of prognosis is crucial for therapeutic decisions. In this study, bioinformatics analysis was used to explore the prognostic value of growth factor receptor-bound protein 2-associated binding protein 3 (GAB3) mRNA. RNA transcriptome sequencing data and clinical data from The Cancer Genome Atlas and genotype-tissue expression (GTEx) were analyzed for differentially expressed genes in high and low GAB3 mRNA expression groups in melanoma...
February 1, 2023: Melanoma Research
https://read.qxmd.com/read/36545919/meva2-1-dova-and-meva2-2-dova-two-novel-brafv600e-driven-mouse-melanoma-cell-lines-to-study-tumor-immune-resistance
#20
JOURNAL ARTICLE
Disha Rao, Ruben Lacroix, Alex Rooker, Tainá Gomes, Johanna A Stunnenberg, Mesele Valenti, Petros Dimitriadis, Chun-Pu Lin, Beaunelle de Bruijn, Oscar Krijgsman, Maarten A Ligtenberg, Daniel S Peeper, Christian U Blank
While immunotherapy has become standard-of-care for cutaneous melanoma patients, primary and acquired resistance prevent long-term benefits for about half of the late-stage patients. Pre-clinical models are essential to increase our understanding of the resistance mechanisms of melanomas, aiming to improve the efficacy of immunotherapy. Here, we present two novel syngeneic transplantable murine melanoma cell lines derived from the same primary tumor induced on BrafV600E Pten-/- mice: MeVa2.1 and MeVa2.2. Derivatives of these cell lines expressing the foreign antigen ovalbumin (dOVA) showed contrasting immune-mediated tumor control...
February 1, 2023: Melanoma Research
journal
journal
30785
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.